An Exploratory Clinical Study of Keynatinib in Relapsed/Refractory B-cell Lymphoma
Latest Information Update: 10 Nov 2023
At a glance
- Drugs Keynatinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; CNS cancer; Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Medolution
- 04 Nov 2023 Planned End Date changed from 10 Apr 2024 to 10 Apr 2028.
- 04 Nov 2023 Planned primary completion date changed from 10 Oct 2023 to 10 Oct 2027.
- 17 Apr 2022 Planned End Date changed from 10 Apr 2023 to 10 Apr 2024.